Suppr超能文献

根据一线抗逆转录病毒治疗方案的类型,病毒学抑制低于 50 HIV-RNA 拷贝/ml 后与残余病毒血症相关的时间。

Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.

机构信息

Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

出版信息

Int J Antimicrob Agents. 2018 Oct;52(4):492-499. doi: 10.1016/j.ijantimicag.2018.07.001. Epub 2018 Sep 13.

Abstract

PURPOSE

To investigate if the regimen used when starting antiretroviral therapy (ART) affects the time spent with residual viraemia (RV) after achieving <50 HIV-RNA copies/mL.

METHODS

Retrospective cohort study on patients infected with human immunodeficiency virus (HIV), followed prospectively, who started ART with a boosted protease inhibitor (PI/r)-, a non-nucleoside reverse transcriptase inhibitor (NNRTI)- or an integrase inhibitor (InSTI)-based triple regimen, or a regimen with more than three drugs. RV was defined as any detectable polymerase chain reaction (PCR) signal <50 HIV-RNA copies/mL, as assessed by kinetic PCR or Abbott real-time PCR. The percentage of time spent with RV (%RV) was calculated as the cumulative follow-up time spent with RV on the observed follow-up, and was estimated using a generalized linear model.

RESULTS

Seven hundred and seventy-one patients (33%, 32%, 30% and 5% receiving PI/r-, NNRTI-, InSTI-based triple regimens, or a regimen with more than three drugs, respectively) were included in the analysis. After a median of 2.16 (interquartile range 1.27-3.16) years of follow-up, adjusted means of %RV were 37.9% [95% confidence interval (CI) 30.3-45.4%], 23.9% (95% CI 16-31.8%), 25.3% (95% CI 17.8-32.7%) and 45.5% (95% CI 34.6-56.4%) in the PI/r, NNRTI, InSTI and more than three drugs groups, respectively; %RV was significantly higher in patients who started ART with a regimen with more than three drugs (P=0.030), and was significantly lower in patients who started ART with an NNRTI-based regimen (P<0.0001) or an InSTI-based regimen (P=0.030) than in those who started ART with a PI/r-based regimen. %RV was independently associated with pre-ART HIV-RNA (P<0.0001), time to HIV-RNA <50 copies/mL (P<0.0001), NRTI backbone (P=0.037) and baseline HIV-RNA (P<0.0001).

CONCLUSION

First-line regimens based on PIs/r or on more than three drugs are associated with a greater percentage of time spent with RV after achieving virological suppression.

摘要

目的

研究起始抗逆转录病毒治疗(ART)时使用的方案是否会影响达到<50 HIV-RNA 拷贝/ml 后残余病毒血症(RV)的持续时间。

方法

这是一项回顾性队列研究,对前瞻性随访的感染人类免疫缺陷病毒(HIV)的患者进行研究,这些患者以增效蛋白酶抑制剂(PI/r)、非核苷类逆转录酶抑制剂(NNRTI)或整合酶抑制剂(INSTI)为基础的三联方案,或使用三种以上药物的方案开始 ART。RV 定义为通过动力学 PCR 或 Abbott 实时 PCR 检测到的任何可检测的聚合酶链反应(PCR)信号<50 HIV-RNA 拷贝/ml。通过广义线性模型计算 RV 持续时间的百分比(%RV),作为观察随访期间 RV 累计随访时间的百分比。

结果

771 例患者(33%、32%、30%和 5%分别接受 PI/r、NNRTI、INSTI 为基础的三联方案或三种以上药物方案)纳入分析。中位随访 2.16 年(四分位间距 1.27-3.16 年)后,调整后的%RV 分别为 37.9%(95%可信区间 30.3-45.4%)、23.9%(95%可信区间 16-31.8%)、25.3%(95%可信区间 17.8-32.7%)和 45.5%(95%可信区间 34.6-56.4%),PI/r、NNRTI、INSTI 和三种以上药物组分别为 37.9%(95%可信区间 30.3-45.4%)、23.9%(95%可信区间 16-31.8%)、25.3%(95%可信区间 17.8-32.7%)和 45.5%(95%可信区间 34.6-56.4%);与起始 ART 时使用三种以上药物的方案相比,起始 ART 时使用三种以上药物的方案的患者的%RV 明显更高(P=0.030),与起始 ART 时使用 NNRTI 为基础的方案(P<0.0001)或 INSTI 为基础的方案(P=0.030)相比,起始 ART 时使用 PI/r 为基础的方案的患者的%RV 明显更低。%RV 与治疗前 HIV-RNA(P<0.0001)、达到 HIV-RNA<50 拷贝/ml 的时间(P<0.0001)、NRTI 骨干(P=0.037)和基线 HIV-RNA(P<0.0001)独立相关。

结论

基于 PI/r 或三种以上药物的一线方案与达到病毒学抑制后 RV 持续时间百分比较高相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验